Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

EYLEA injection shows better gains in visual acuity than both bevacizumab and ranibizumab in NIH-sponsored DME study Regeneron Pharmaceuticals, has announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA (aflibercept) Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both bevacizumab (Avastin/Genentech) and ranibizumab injection (Lucentis/Genentech), the primary endpoint of the study.
Drug Research > Drug Discovery & Development > News
GSK update on current development status of the GSK/NIH Ebola vaccine candidate With the Ebola crisis in West Africa continuing, GSK is working closely with the World Health Organization (WHO), regulators and other partners to respond to the outbreak, to accelerate development of our investigational Ebola vaccine and to ramp up production as quickly as possible.
Drug Research > Drug Discovery & Development > News NeuroSigma, US Veterans Administration (VA) enter into cooperative research and development agreement NeuroSigma a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs (VA) for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Bristol-Myers, Pharmacyclics and Janssen collaborate for new non-hodgkin lymphoma drug
By PBR Staff Writer
Bristol-Myers Squibb (BMS), Pharmacyclics and Janssen Research & Development have entered into collaboration to conduct a Phase I/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination of Opdivo and Imbruvica in patients with non-Hodgkin lymphoma (NHL).
Drug Research > Drug Discovery & Development > News
HemoShear completes initial development phase of new cancer drug discovery platform
By PBR Staff Writer
HemoShear has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.
Drug Research > Drug Discovery & Development > News
Pharmaceutical firms to use UC San Diego-led resource to share data for drug design
By PBR Staff Writer
Pharmaceutical companies will collaborate with researchers at the University of California, San Diego to provide previously unreleased proprietary data for drug discovery through a new $3.7m effort funded by the National Institutes for Health.
Drug Research > Drug Discovery & Development > News
Blaze Bioscience gets SBIR phase II funding for clinical trial of tumor paint BLZ-100 in sarcoma
Blaze Bioscience, a biotechnology company focused on guided cancer therapy, has been awarded a $1.5m Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma.
Drug Research > Drug Discovery & Development > News
EMD Serono, ICR, Wellcome Trust collaborate to develop anti-cancer drugs
By PBR Staff Writer
Merck subsidiary EMD Serono, the Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and license agreement for developing new drug candidates to treat different forms of cancer.
Drug Research > Drug Discovery & Development > News
DiscoveryBioMed awarded Dual SBIR awards for PKD drug discovery and validation
DiscoveryBioMed learned in recent months that it was awarded a new Phase 1 SBIR grant from the National Institutes of Health (NIH) to perform high-throughput screening (HTS)-based drug discovery and validation to discover novel small molecules that attack the secondary phase of autosomal dominant polycystic kidney disease (ADPKD).
Drug Research > Drug Discovery & Development > News
FeF Chemicals - Insulin Human and Benzalkonium Chloride Products
FeF Chemicals is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.
Drug Research > Drug Discovery & Development > Suppliers
BrainStorm reports last patient visit in Phase IIa ALS trial
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, has announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn in Amyotrophic Lateral Sclerosis (ALS), conducted at the Hadassah Medical Center in Jerusalem.
Drug Research > Drug Discovery & Development > News
Eleven Biotherapeutics report top-line results from Phase II trial of EBI-005
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, has announced top-line results from a Phase 2 study of its lead drug candidate, EBI-005, in patients with moderate to severe allergic conjunctivitis.
Drug Research > Drug Discovery & Development > News
China Oncology to develop and commercialize Sorrento's anti-PD-L1 antibody
By PBR Staff Writer
Lee's Pharma affiliate China Oncology Focus has secured license from US-based Sorrento Therapeutics for its fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250